Acid Reflux News and Research

RSS

Acid reflux disease is a condition that often results when a valve located at the end of the esophagus malfunctions. When this valve relaxes inappropriately, it may allow stomach acid to splash up and irritate the lining of the esophagus, creating the sensation called heartburn, and other uncomfortable symptoms. Frequent, persistent heartburn is the primary symptom associated with acid reflux disease or GERD.

Los Alamos team sees unprecedented proof of ion's role in enzymatic process

A Los Alamos National Laboratory research team has harnessed neutrons to view for the first time the critical role that an elusive molecule plays in certain biological reactions. The effort could aid in treatment of peptic ulcers or acid reflux disease, or allow for more efficient conversion of woody waste into transportation fuels.

9 Aug 2011

Study helps clarify definition of gastroesophageal reflux disease

Modifying stomach acid levels may not be enough to treat symptoms in neonates suspected of having gastroesophageal reflux disease. According to a study from Nationwide Children's Hospital, this is the first study to classify reflux and its associated symptoms in neonates based on how and what is refluxed.

9 Aug 2011

VeganZyme supplement may aid in reducing digestive discomfort and symptoms

Every year the American public spends billions of dollars on food and beverages that are toxic to the body and devoid of natural enzymes. These may include processed, microwaved or cooked food, meat, cereal grains, milk, gluten, soy, refined sugar, and more. But are they really getting their money's worth? Not without a little extra help, says Dr. Edward F. Group III, DC, ND, a world-renowned authority on natural medicine and digestive health.

26 Jul 2011

Scientists discover origin of Barrett's esophagus

Dr Frank McKeon, Senior Group Leader of the Stem Cell and Developmental Biology at A*STAR's Genome Institute of Singapore, and Principal Investigator Dr Wa Xian at A*STAR's Institute of Medical Biology, together with their counterparts from the Harvard Medical School, the Brigham and Women's Hospital in Boston, and the National University of Singapore, have made the striking finding that Barrett's esophagus work, published online in the journal Cell on 24 June 2011, is essential to developing therapeutics for esophageal cancer.

28 Jun 2011

Study traces precursor of deadly esophageal cancers to leftover embryonic cells

The ultimate source of some cancers is embryonic cells. Research published in the June 24th Cell, a Cell Press publication, traces the precursor of deadly esophageal cancers to leftover embryonic cells found in all adults.

24 Jun 2011

Researchers discover new mechanism for origin of Barrett's esophagus

Researchers have discovered a new mechanism for the origin of Barrett's esophagus, an intestine-like growth in the esophagus that is triggered by chronic acid reflux and often progresses to esophageal cancer.

24 Jun 2011

AGA guidelines recommend RFA for removal of precancerous cells in patients with Barrett's esophagus

New guidelines issued by the American Gastroenterological Association (AGA) support the use of radiofrequency ablation (RFA) to remove precancerous cells in patients with Barrett's esophagus, a condition most commonly caused by chronic acid reflux, or GERD. Barrett's esophagus is the leading cause of esophageal cancer and affects an estimated two million Americans.

5 Apr 2011

AstraZeneca, AmeriCares partner to deliver medicines for people with chronic conditions

AmeriCares and AstraZeneca have teamed to deliver critical medicines to help people living with chronic diseases throughout the United States. AstraZeneca has donated $5 million in cardiovascular and gastrointestinal medications to AmeriCares in support of its Domestic Medical Assistance Program.

29 Mar 2011

DISCUSS survey findings highlight need to prioritize GERD dialogue

According to findings from the new nationwide DISCUSS Survey, many people surveyed report that their gastroesophageal reflux disease and/or persistent heartburn symptoms significantly disrupt their lives.

24 Mar 2011

Chemist discover new strategy to process certain drugs

A prolific University of Missouri chemist has discovered a quicker and easier method for pharmaceutical companies to make certain drugs.

9 Mar 2011

IRB approves Guided Therapeutics light-based Barrett's Esophagus detection technology for human trial

Guided Therapeutics, Inc., developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it has received Institutional Review Board approval to begin testing its light-based detection technology in humans for Barrett's Esophagus, a precursor for esophageal cancer.

8 Mar 2011

FDA issues Complete Response Letter for approval of Eisai's rabeprazole sodium extended-release capsules

Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.

2 Feb 2011

Tiny light source and sensors in endoscope may detect esophageal cancer more accurately

A tiny light source and sensors at the end of an endoscope may provide a more accurate way to identify pre-cancerous cells in the lining of the esophagus.

4 Jan 2011

Cascade reaffirms position on non-invasive detection of melanoma by SkinSpect device

Cascade Technologies, Corp. announced today that, in response to significant recent attention to the Food and Drug Administration (FDA) panel evaluation of Mela Sciences' MelaFind device, the company has received a number of inquiries about its similar instrument.

20 Nov 2010

Spectral Molecular Imaging awarded $190,172 QTDP grant for development of melanoma detection system

Cascade Technologies Corp., announced today that its wholly-owned subsidiary Spectral Molecular Imaging, Inc. (SMI) has received a grant under the Qualifying Therapeutic Discovery Project (QTDP) program to advance the development of the company's SkinSpect system for the detection of melanoma and other skin cancers.

9 Nov 2010

Cascade enters non-binding letter of intent to acquire AcuNetx

Cascade Technologies Corp. announced today that it has entered into a non-binding letter of intent to acquire all of the assets of AcuNetx, Inc., a Nevada corporation in exchange for common stock of Cascade.

2 Nov 2010

Glaxo to pay $750 million settlement for defective, unsafe medicines

The New York Times: "GlaxoSmithKline, the British drug giant, has agreed to pay $750 million to settle criminal and civil complaints that the company for years knowingly sold contaminated baby ointment and an ineffective antidepressant — the latest in a growing number of whistle-blower lawsuits that drug makers have settled with multimillion-dollar fines." The 20 medicines that were produced with "questionable safety" measures included "Avandia, a troubled diabetes drug; Coreg, a heart drug; and Tagamet an acid reflux drug."

28 Oct 2010

Glaxo to pay $750 million in defective drug settlement

GlaxoSmithKline Plc, one of the world’s largest pharmaceutical companies, has agreed to pay $750 million to settle a U.S. government false-claims lawsuit over the sale of defective drugs. The lawsuit first filed in 2004 by Cheryl D. Eckard, a former global quality assurance manager for the London-based company came to a settlement finally. Eckard, 51, said, “This is not something I wanted to do, but because of patient safety it was necessary.” Being the one to bring this to notice she would receive $96 million from the settlement money. She had warned the company earlier but was fired because of her efforts.

26 Oct 2010

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

Many of the world's preeminent gastroenterologists will gather for the American College of Gastroenterology's (ACG) 75th Annual Scientific Meeting at the Henry B. Gonzalez Convention Center in San Antonio, Texas starting Monday October 18, 2010, to review the latest scientific advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.

19 Oct 2010

Studies explore impact of upper GI conditions on sleep

The impact of upper GI conditions, like gastroesophageal reflux disease (GERD) and functional dyspepsia, on sleep—and treatments aimed at providing relief to heartburn/acid reflux patients who suffer from disordered sleep—were explored in three new studies related to sleep dysfunction presented today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.

18 Oct 2010